We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OGT Grants DNA Sequence Variation Licence to Biotype Diagnostics GmbH
News

OGT Grants DNA Sequence Variation Licence to Biotype Diagnostics GmbH

OGT Grants DNA Sequence Variation Licence to Biotype Diagnostics GmbH
News

OGT Grants DNA Sequence Variation Licence to Biotype Diagnostics GmbH

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OGT Grants DNA Sequence Variation Licence to Biotype Diagnostics GmbH"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology (OGT) and Biotype Diagnostics GmbH are to announce the completion of a licence agreement granting Biotype access to OGT patents for the detection of DNA sequence variations. The licence, which will remain valid for the lifetime of the patents, provides Biotype with certain rights with respect to SNP genotyping.

Sue Sutton, VP Business Development at OGT, said: “OGT continues to develop its licensing programme and is pleased to license our sequence variation patents to Biotype. These patents are an important part of OGT’s broad patent portfolio and, together with Biotype’s microarray platform, gives customers access to a new, comprehensive way of detecting commercially important wood-rotting fungi.”

Wilhelm Zorgiebel, Executive Director at Biotype, commented: "We are pleased to enter into this licensing arrangement with OGT, a company that is recognized as being at the forefront of molecular technology. This agreement helps us to develop our own microarray technology platform for various applications in medicine and analytics. Our first product, which is completely unique in the market, is the Mycotype® BasidioQS Microarray Detection Kit, which allows the fast and sensitive, simultaneous analysis of the 27 most important wood-rotting basidiomycetes in Europe.”
Advertisement